Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia
RATIONALE: Polyunsaturated fatty acids are important for normal growth and development. One type, called omega-3 fatty acids (found in fish, fish oil, and some other foods), may affect the growth of abnormal breast cells.
PURPOSE: This randomized pilot trial is studying how well omega-3 fatty acids work in treating women with newly diagnosed ductal carcinoma in situ and/or atypical ductal hyperplasia.
|Breast Cancer Precancerous Condition||Dietary Supplement: omega-3 fatty acid Other: placebo|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
|Official Title:||Omega-3 Fatty Acids and Prevention of DCIS and/or ADH: A Translational Approach|
- Effect of omega-3 fatty acids on markers of breast cancer progression [ Time Frame: minimum 2 weeks, maximum 8 weeks ]
|Study Start Date:||December 2007|
|Study Completion Date:||November 2013|
|Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Experimental: Arm I
Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8 weeks.
Dietary Supplement: omega-3 fatty acid
Oral, 3 times daily
Placebo Comparator: Arm II
Patients receive oral placebo olive oil capsules 3 times daily for up to 8 weeks.
Oral, 3 times daily
- To determine the effect of omega-3 fatty acids on markers of breast cancer progression in women with newly diagnosed ductal carcinoma in situ and/or atypical ductal hyperplasia.
- To determine the effect of omega-3 fatty acids on specific targets identified by microarray in breast cancer cells and in primary cultures from benign and malignant breast tissue biopsies.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8 weeks.
- Arm II: Patients receive oral placebo olive oil capsules 3 times daily for up to 8 weeks.
Patients complete questionnaires at baseline, weekly during study treatment, at the completion of study treatment, and then at 30 days after completion of study treatment. These questionnaires include the Fish Oil Adverse Event Questionnaire, the Diet and Family History Questionnaire, the Changes to Diet and Medications Questionnaire, and the Post-Intervention Questionnaire.
Patients undergo blood, urine, nipple aspirate, and tissue sample collection at baseline and after completion of study treatment for translational research studies. Blood samples are analyzed for genetic markers for breast cancer risk and progression by microarray analysis and red blood cell (RBC) fatty acids. Nipple aspirate samples are analyzed for fatty acids to determine the extent to which omega-3 fatty acid supplementation alters the fatty acid profile of breast tissue. Tissue samples are analyzed for the presence of ductal carcinoma in situ and/or atypical ductal hyperplasia or invasive cancer. Leftover blood, urine, nipple aspirate, and tissue samples are stored for future research studies.
After completion of study treatment, patients are followed at 30 days.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00627276
|United States, Oregon|
|Portland, Oregon, United States, 97220|
|Knight Cancer Institute at Oregon Health and Science University|
|Portland, Oregon, United States, 97239-3098|
|Principal Investigator:||Jackilen Shannon, PhD||OHSU Knight Cancer Institute|